Mangalam Drugs and Organics Ltd

₹ 108 2.49%

04 Jul 4:01 p.m.

mangalamdrugs.com BSE: 532637 NSE: MANGALAM

About

Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates^[1]

Key Points

Business Overview:^[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations

Website BSE NSE

Market Cap ₹ 171 Cr.
Current Price ₹ 108
High / Low ₹ 132 / 85.2
Stock P/E
Book Value ₹ 89.9
Dividend Yield 0.00 %
ROCE 1.19 %
ROE -6.15 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Debtor days have improved from 37.0 to 27.7 days.

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 10.1% over past five years.
Company has a low return on equity of 2.69% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	92.90	104.78	123.02	101.88	120.96	109.49	108.33	63.32	91.11	87.46	81.56	97.34	102.24
	81.32	94.43	109.26	87.56	110.77	99.12	99.89	56.84	90.87	90.94	79.37	90.36	90.54
Operating Profit	11.58	10.35	13.76	14.32	10.19	10.37	8.44	6.48	0.24	-3.48	2.19	6.98	11.70
OPM %	12.47%	9.88%	11.19%	14.06%	8.42%	9.47%	7.79%	10.23%	0.26%	-3.98%	2.69%	7.17%	11.44%
	0.00	0.52	0.00	0.00	0.00	0.01	0.00	0.13	0.29	0.02	0.03	0.00	0.05
Interest	2.22	2.96	2.98	2.69	2.53	3.54	2.56	3.22	3.43	3.41	3.24	3.31	3.95
Depreciation	2.52	2.39	2.50	2.67	2.69	2.60	2.76	2.88	2.75	3.42	3.73	3.62	3.86
Profit before tax	6.84	5.52	8.28	8.96	4.97	4.24	3.12	0.51	-5.65	-10.29	-4.75	0.05	3.94
Tax %	68.57%	19.93%	45.41%	55.02%	-34.61%	29.01%	28.85%	15.69%	22.30%	7.29%	25.05%	-920.00%	9.90%
	2.15	4.42	4.53	4.02	6.69	3.00	2.23	0.43	-4.39	-9.54	-3.56	0.50	3.55
EPS in Rs	1.36	2.79	2.86	2.54	4.23	1.90	1.41	0.27	-2.77	-6.03	-2.25	0.32	2.24
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	124	123	221	295	299	269	228	282	380	451	372	369
	129	113	200	257	252	222	218	259	327	402	347	351
Operating Profit	-4	10	20	38	47	47	10	24	53	49	26	17
OPM %	-4%	8%	9%	13%	16%	17%	4%	8%	14%	11%	7%	5%
	2	0	0	0	-0	1	0	1	5	0	0	0
Interest	10	10	10	9	10	12	9	10	9	11	13	14
Depreciation	4	4	4	4	5	7	7	8	9	10	11	15
Profit before tax	-17	-4	6	24	31	29	-6	6	40	28	2	-11
Tax %	30%	22%	-2%	33%	29%	32%	-40%	-32%	29%	29%	43%	18%
	-12	-3	6	16	22	20	-8	8	28	20	1	-9
EPS in Rs	-8.95	-2.31	4.66	11.15	14.08	12.57	-5.07	5.21	17.67	12.42	0.80	-5.72
Dividend Payout %	0%	0%	0%	0%	0%	4%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	12%
5 Years:	10%
3 Years:	-1%
TTM:	-1%

Compounded Profit Growth
10 Years:	%
5 Years:	-3%
3 Years:	%
TTM:	-813%

Stock Price CAGR
10 Years:	27%
5 Years:	29%
3 Years:	-13%
1 Year:	0%

Return on Equity
10 Years:	11%
5 Years:	7%
3 Years:	3%
Last Year:	-6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	13	13	13	14	16	16	16	16	16	16	16	16
Reserves	13	10	16	39	70	88	80	88	115	135	136	127
	73	77	78	60	66	69	65	52	70	88	89	98
	16	25	63	47	38	54	50	75	64	90	119	116
Total Liabilities	115	125	170	160	190	227	211	231	264	328	360	357
	55	53	53	54	93	102	103	101	118	135	142	155
CWIP	0	0	0	5	0	0	0	1	6	6	9	0
Investments	0	0	0	0	2	0	0	0	0	0	0	0
	59	72	117	100	95	125	107	128	140	188	208	202
Total Assets	115	125	170	160	190	227	211	231	264	328	360	357

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	-1	7	14	22	43	25	22	31	28	26	40	12
	-2	-2	-4	-11	-39	-16	-9	-7	-31	-27	-22	-18
	2	-5	-10	-11	-3	-9	-11	-23	3	3	-17	6
Net Cash Flow	-1	0	1	-0	0	-0	1	0	-1	1	1	-0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	70	88	73	37	45	61	28	52	52	38	46	28
Inventory Days	112	170	134	85	69	132	175	121	85	139	200	185
Days Payable	39	97	128	37	38	82	77	106	63	65	141	124
Cash Conversion Cycle	144	161	79	85	75	111	126	67	74	112	104	88
Working Capital Days	125	122	79	76	70	99	102	66	75	84	93	97
ROCE %	-7%	6%	16%	30%	32%	25%	2%	11%	27%	18%	6%

Shareholding Pattern

Numbers in percentages

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	50.53%	50.53%	50.53%	50.53%	50.42%	50.41%	50.31%	50.31%	50.31%	50.31%	50.31%	50.31%
	0.00%	0.00%	0.00%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.26%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	49.46%	49.46%	49.46%	49.36%	49.47%	49.49%	49.58%	49.59%	49.58%	49.59%	49.59%	49.42%
No. of Shareholders	21,827	21,071	20,668	20,084	18,988	18,483	17,911	17,943	17,890	17,978	18,610	19,173

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	50.76%	50.76%	49.27%	50.53%	50.53%	50.53%	50.31%	50.31%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.10%	0.26%
	0.19%	0.25%	1.29%	0.01%	0.01%	0.01%	0.00%	0.00%
	49.05%	48.99%	49.44%	49.46%	49.46%	49.36%	49.59%	49.42%
No. of Shareholders	15,529	18,113	19,611	17,884	20,520	20,084	17,943	19,173

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls